File Download
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1038/srep09979
- Scopus: eid_2-s2.0-84928382257
- PMID: 25897700
- WOS: WOS:000353280700003
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Therapeutic targeting of CBP/β-catenin signaling reduces cancer stem-like population and synergistically suppresses growth of EBV-positive nasopharyngeal carcinoma cells with cisplatin
Title | Therapeutic targeting of CBP/β-catenin signaling reduces cancer stem-like population and synergistically suppresses growth of EBV-positive nasopharyngeal carcinoma cells with cisplatin |
---|---|
Authors | |
Issue Date | 2015 |
Publisher | Nature Publishing Group. The Journal's web site is located at http://www.nature.com/srep/index.html |
Citation | Scientific Reports, 2015, v. 5, article no. 9979 How to Cite? |
Abstract | Nasopharyngeal carcinoma (NPC) is an EBV-associated epithelial malignancy prevalent in southern China. Presence of treatment-resistant cancer stem cells (CSC) may associate with tumor relapse and metastasis in NPC. ICG-001 is a specific CBP/β-catenin antagonist that can block CBP/β-catenin-mediated transcription of stem cell associated genes and enhance p300/β-catenin-mediated transcription, thereby reducing the CSC-like population via forced differentiation. In this study, we aimed to evaluate the effect of ICG-001 on the CSC-like population, and the combination effect of ICG-001 with cisplatin in the C666-1 EBV-positive NPC cells. Results showed that ICG-001 inhibited C666-1 cell growth and reduced expression of CSC-associated proteins with altered expression of epithelial-mesenchymal transition (EMT) markers. ICG-001 also inhibited C666-1 tumor sphere formation, accompanied with reduced SOX2 hi /CD44 hi CSC-like population. ICG-001 was also found to restore the expression of a tumor suppressive microRNA-145 (miR-145). Ectopic expression of miR-145 effectively repressed SOX2 protein expression and inhibited tumor sphere formation. Combination of ICG-001 with cisplatin synergistically suppressed in vitro growth of C666-1 cells and significantly suppressed growth of NPC xenografts. These results suggested that therapeutically targeting of the CBP/β-catenin signaling pathway with ICG-001 can effectively reduce the CSC-like population and combination with cisplatin can effectively suppress the growth of NPC. |
Persistent Identifier | http://hdl.handle.net/10722/211611 |
ISSN | 2023 Impact Factor: 3.8 2023 SCImago Journal Rankings: 0.900 |
PubMed Central ID | |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Chan, KC | - |
dc.contributor.author | Chan, LS | - |
dc.contributor.author | Ip, JCY | - |
dc.contributor.author | Lo, C | - |
dc.contributor.author | Yip, TTC | - |
dc.contributor.author | Ngan, RKC | - |
dc.contributor.author | Wong, RNS | - |
dc.contributor.author | Lo, KW | - |
dc.contributor.author | Ng, WT | - |
dc.contributor.author | Lee, AWM | - |
dc.contributor.author | Tsao, GSW | - |
dc.contributor.author | Kahn, M | - |
dc.contributor.author | Mak, NK | - |
dc.contributor.author | Lung, ML | - |
dc.date.accessioned | 2015-07-21T02:04:42Z | - |
dc.date.available | 2015-07-21T02:04:42Z | - |
dc.date.issued | 2015 | - |
dc.identifier.citation | Scientific Reports, 2015, v. 5, article no. 9979 | - |
dc.identifier.issn | 2045-2322 | - |
dc.identifier.uri | http://hdl.handle.net/10722/211611 | - |
dc.description.abstract | Nasopharyngeal carcinoma (NPC) is an EBV-associated epithelial malignancy prevalent in southern China. Presence of treatment-resistant cancer stem cells (CSC) may associate with tumor relapse and metastasis in NPC. ICG-001 is a specific CBP/β-catenin antagonist that can block CBP/β-catenin-mediated transcription of stem cell associated genes and enhance p300/β-catenin-mediated transcription, thereby reducing the CSC-like population via forced differentiation. In this study, we aimed to evaluate the effect of ICG-001 on the CSC-like population, and the combination effect of ICG-001 with cisplatin in the C666-1 EBV-positive NPC cells. Results showed that ICG-001 inhibited C666-1 cell growth and reduced expression of CSC-associated proteins with altered expression of epithelial-mesenchymal transition (EMT) markers. ICG-001 also inhibited C666-1 tumor sphere formation, accompanied with reduced SOX2 hi /CD44 hi CSC-like population. ICG-001 was also found to restore the expression of a tumor suppressive microRNA-145 (miR-145). Ectopic expression of miR-145 effectively repressed SOX2 protein expression and inhibited tumor sphere formation. Combination of ICG-001 with cisplatin synergistically suppressed in vitro growth of C666-1 cells and significantly suppressed growth of NPC xenografts. These results suggested that therapeutically targeting of the CBP/β-catenin signaling pathway with ICG-001 can effectively reduce the CSC-like population and combination with cisplatin can effectively suppress the growth of NPC. | - |
dc.language | eng | - |
dc.publisher | Nature Publishing Group. The Journal's web site is located at http://www.nature.com/srep/index.html | - |
dc.relation.ispartof | Scientific Reports | - |
dc.rights | This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. | - |
dc.title | Therapeutic targeting of CBP/β-catenin signaling reduces cancer stem-like population and synergistically suppresses growth of EBV-positive nasopharyngeal carcinoma cells with cisplatin | - |
dc.type | Article | - |
dc.identifier.email | Ip, JCY: josephip@hku.hk | - |
dc.identifier.email | Lee, AWM: awmlee@hkucc.hku.hk | - |
dc.identifier.email | Tsao, GSW: gswtsao@hku.hk | - |
dc.identifier.email | Lung, ML: mlilung@hku.hk | - |
dc.identifier.authority | Lee, AWM=rp02056 | - |
dc.identifier.authority | Tsao, GSW=rp00399 | - |
dc.identifier.authority | Lung, ML=rp00300 | - |
dc.description.nature | published_or_final_version | - |
dc.identifier.doi | 10.1038/srep09979 | - |
dc.identifier.pmid | 25897700 | - |
dc.identifier.pmcid | PMC4404684 | - |
dc.identifier.scopus | eid_2-s2.0-84928382257 | - |
dc.identifier.hkuros | 244743 | - |
dc.identifier.volume | 5 | - |
dc.identifier.spage | article no. 9979 | - |
dc.identifier.epage | article no. 9979 | - |
dc.identifier.isi | WOS:000353280700003 | - |
dc.publisher.place | United Kingdom | - |
dc.identifier.issnl | 2045-2322 | - |